FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030558566> ?p ?o ?g. }

• W3030558566 endingPage "e17075" @default.
• W3030558566 startingPage "e17075" @default.
• W3030558566 abstract "e17075 Background: Real-world evidence is urgently needed to monitor the translation of new treatment approaches into routine clinical practice as well as to improve cancer treatment and survivorship care. Methods: PAZOREAL is a prospective, multicenter, non-interventional study to evaluate effectiveness, tolerability, safety, and quality of life (QoL) in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) treated with 1st-line pazopanib (PAZO) followed by 2nd-line nivolumab (NIVO). The primary variable was time on drug (TD) in the respective treatment (Tx) lines. Other endpoints include overall survival (OS), safety and QoL evaluated by EQ-5D-5L. Results: Between December 2015 and September 2017, 414 pts were enrolled and 388 pts started first-line PAZO Tx, 136 pts subsequently received NIVO as second-line Tx. At time of data-cut (30 Sep 2019) median TD was 6.5 months (95%CI 5.7-7.6) for 1st-line PAZO and 4.6 months (95%CI 3.3-6.0) for 2nd-line NIVO. 9.0% of 1st-line PAZO pts and 5.9% of 2nd-line NIVO pts achieved a complete response and disease control rate was 58.0% (95% CI 53.0-62.8) and 44.9% (95% CI 36.8-53.2) for PAZO or NIVO, respectively. Median OS was 32.6 months (95% CI 28.0-38.9) for all pts, 32.6 months (95%CI 28.2-NA) for pts with 2nd-line NIVO and 32.3 months (95%CI 18.8-NA) for pts with other 2nd-line Tx. The most commonly reported treatment emergent AEs were diarrhea (37.2%), nausea (21.7%) and fatigue (19.1%) for PAZO Tx and diarrhea (8.8%), peripheral edema (5.9%) and dyspnea, fatigue, nausea, rash, vomiting (5.1% each) for NIVO. 66 pts (17.1%) discontinued PAZO and 7 pts (5.1%) discontinued NIVO due to related TEAEs. During 1st-line PAZO Tx, mean EQ-5D-5L utility scores initially decreased slightly by time, returned to baseline level and remained stable afterwards. During 2nd-line NIVO Tx the utility scores initially increased by time and remained stable thereafter. Similar tendencies were reported for mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Conclusions: The interim results of the PAZOREAL study confirm favorable clinical trial outcomes, the good benefit-risk profile and the sustained QoL in pts with mRCC in a real-world setting. The sequential treatment with PAZO followed by NIVO is effective and well tolerated. Clinical trial information: NIS-Nr.: 6687." @default.
• W3030558566 created "2020-06-05" @default.
• W3030558566 creator A5001987856 @default.
• W3030558566 creator A5004618159 @default.
• W3030558566 creator A5018450987 @default.
• W3030558566 creator A5018733361 @default.
• W3030558566 creator A5036944164 @default.
• W3030558566 creator A5042953744 @default.
• W3030558566 creator A5043019017 @default.
• W3030558566 creator A5050204860 @default.
• W3030558566 creator A5051003180 @default.
• W3030558566 creator A5062182046 @default.
• W3030558566 creator A5065276471 @default.
• W3030558566 creator A5066991388 @default.
• W3030558566 creator A5071178428 @default.
• W3030558566 creator A5079462263 @default.
• W3030558566 date "2020-05-20" @default.
• W3030558566 modified "2023-09-23" @default.
• W3030558566 title "Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL." @default.
• W3030558566 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e17075" @default.
• W3030558566 hasPublicationYear "2020" @default.
• W3030558566 type Work @default.
• W3030558566 sameAs 3030558566 @default.
• W3030558566 citedByCount "1" @default.
• W3030558566 countsByYear W30305585662022 @default.
• W3030558566 crossrefType "journal-article" @default.
• W3030558566 hasAuthorship W3030558566A5001987856 @default.
• W3030558566 hasAuthorship W3030558566A5004618159 @default.
• W3030558566 hasAuthorship W3030558566A5018450987 @default.
• W3030558566 hasAuthorship W3030558566A5018733361 @default.
• W3030558566 hasAuthorship W3030558566A5036944164 @default.
• W3030558566 hasAuthorship W3030558566A5042953744 @default.
• W3030558566 hasAuthorship W3030558566A5043019017 @default.
• W3030558566 hasAuthorship W3030558566A5050204860 @default.
• W3030558566 hasAuthorship W3030558566A5051003180 @default.
• W3030558566 hasAuthorship W3030558566A5062182046 @default.
• W3030558566 hasAuthorship W3030558566A5065276471 @default.
• W3030558566 hasAuthorship W3030558566A5066991388 @default.
• W3030558566 hasAuthorship W3030558566A5071178428 @default.
• W3030558566 hasAuthorship W3030558566A5079462263 @default.
• W3030558566 hasConcept C121608353 @default.
• W3030558566 hasConcept C126322002 @default.
• W3030558566 hasConcept C141071460 @default.
• W3030558566 hasConcept C143998085 @default.
• W3030558566 hasConcept C197934379 @default.
• W3030558566 hasConcept C203092338 @default.
• W3030558566 hasConcept C2777472916 @default.
• W3030558566 hasConcept C2777701055 @default.
• W3030558566 hasConcept C2778375690 @default.
• W3030558566 hasConcept C2778439243 @default.
• W3030558566 hasConcept C2779490328 @default.
• W3030558566 hasConcept C2780030458 @default.
• W3030558566 hasConcept C535046627 @default.
• W3030558566 hasConcept C61943457 @default.
• W3030558566 hasConcept C71924100 @default.
• W3030558566 hasConceptScore W3030558566C121608353 @default.
• W3030558566 hasConceptScore W3030558566C126322002 @default.
• W3030558566 hasConceptScore W3030558566C141071460 @default.
• W3030558566 hasConceptScore W3030558566C143998085 @default.
• W3030558566 hasConceptScore W3030558566C197934379 @default.
• W3030558566 hasConceptScore W3030558566C203092338 @default.
• W3030558566 hasConceptScore W3030558566C2777472916 @default.
• W3030558566 hasConceptScore W3030558566C2777701055 @default.
• W3030558566 hasConceptScore W3030558566C2778375690 @default.
• W3030558566 hasConceptScore W3030558566C2778439243 @default.
• W3030558566 hasConceptScore W3030558566C2779490328 @default.
• W3030558566 hasConceptScore W3030558566C2780030458 @default.
• W3030558566 hasConceptScore W3030558566C535046627 @default.
• W3030558566 hasConceptScore W3030558566C61943457 @default.
• W3030558566 hasConceptScore W3030558566C71924100 @default.
• W3030558566 hasFunder F4320332736 @default.
• W3030558566 hasIssue "15_suppl" @default.
• W3030558566 hasLocation W30305585661 @default.
• W3030558566 hasOpenAccess W3030558566 @default.
• W3030558566 hasPrimaryLocation W30305585661 @default.
• W3030558566 hasRelatedWork W2052289160 @default.
• W3030558566 hasRelatedWork W2518309888 @default.
• W3030558566 hasRelatedWork W2599411294 @default.
• W3030558566 hasRelatedWork W2894779831 @default.
• W3030558566 hasRelatedWork W2895870246 @default.
• W3030558566 hasRelatedWork W2912727504 @default.
• W3030558566 hasRelatedWork W3087328364 @default.
• W3030558566 hasRelatedWork W3210028029 @default.
• W3030558566 hasRelatedWork W4247404453 @default.
• W3030558566 hasRelatedWork W53594158 @default.
• W3030558566 hasVolume "38" @default.
• W3030558566 isParatext "false" @default.
• W3030558566 isRetracted "false" @default.
• W3030558566 magId "3030558566" @default.
• W3030558566 workType "article" @default.